Ansun Biopharma, Inc. [clinicaltrials_resource:62c3922ab2d34502194750102b5743a2]
Single Dose Escalating Study of DAS181 in Adults [clinicaltrials:NCT00527865]DAS181 Single Dose Escalation Study in Healthy Adults [clinicaltrials:NCT00876161]Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza [clinicaltrials:NCT01037205]clinicaltrials:NCT01113034
collaborator [clinicaltrials_vocabulary:collaborator]
Single Dose Escalating Study of DAS181 in Adults [clinicaltrials:NCT00527865]DAS181 Single Dose Escalation Study in Healthy Adults [clinicaltrials:NCT00876161]Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza [clinicaltrials:NCT01037205]clinicaltrials:NCT01113034A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen [clinicaltrials:NCT01644877]Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza [clinicaltrials:NCT01740063]An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [clinicaltrials:NCT01924793]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Single Dose Escalating Study of DAS181 in Adults [clinicaltrials:NCT00527865]DAS181 Single Dose Escalation Study in Healthy Adults [clinicaltrials:NCT00876161]Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza [clinicaltrials:NCT01037205]clinicaltrials:NCT01113034A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen [clinicaltrials:NCT01644877]Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza [clinicaltrials:NCT01740063]An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection [clinicaltrials:NCT01924793]
source [clinicaltrials_vocabulary:source]
Ansun Biopharma, Inc. [clinicaltrials_resource:62c3922ab2d34502194750102b5743a2]
Bio2RDF identifier
62c3922ab2d34502194750102b5743a2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:62c3922ab2d34502194750102b5743a2
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:62c3922ab2d34502194750102b5743a2
title
Ansun Biopharma, Inc.
@en
type
label
Ansun Biopharma, Inc. [clinicaltrials_resource:62c3922ab2d34502194750102b5743a2]
@en